Showing results (11-20 of 32) with videos related to
Sort By:
Pageof 4
British Journal of Haematology|January 9, 2013
Presenting D-dimer and early symptom severity are independent predictors for post-thrombotic syndrome following a first deep vein thrombosisLara N Roberts, Raj K Patel, Paradzai B Chitongo, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 30, 2013
Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generationMohamed Habib, Lara N Roberts, Raj K Patel, et al.Surgery|September 22, 2024
Infant bronchial tree simulator: Success of a built-from-scratch model for single lung isolationRaj K Patel, Ruchika Gupta, Elizabeth S Reinhart, et al.Journal of Vascular Surgery. Venous and Lymphatic Disorders|March 8, 2016
Relationship between development of post-thrombotic syndrome and serial ultrasound, D-dimer, and factor VIII activity after a first deep venous thrombosisLara N Roberts, Raj K Patel, David E Goss, et al.Journal of Vascular Surgery|January 29, 2009
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutationFaisal R Ali, Lara N Roberts, Hiren Mistry, et al.Circulation|August 14, 2013
Population pharmacokinetics of enoxaparin during the antenatal periodJignesh P Patel, Bruce Green, Raj K Patel, et al.Research and Practice in Thrombosis and Haemostasis|November 1, 2021
Rivaroxaban in acute venous thromboembolism: UK prescribing experienceVictoria Speed, Jignesh P Patel, Derek Cooper, et al.Chest|May 18, 2013
Comprehensive VTE prevention program incorporating mandatory risk assessment reduces the incidence of hospital-associated thrombosisLara N Roberts, Gayle Porter, Richard D Barker, et al.Research and Practice in Thrombosis and Haemostasis|July 27, 2018
The impact of body weight on rivaroxaban pharmacokineticsSarah J Barsam, Jignesh P Patel, Lara N Roberts, et al.Journal of Thrombosis and Thrombolysis|June 7, 2019
What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trialZara Sayar, Julia Czuprynska, Jignesh P Patel, et al.Pageof 4